KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Free Cash Flow (2017 - 2025)

Amneal Pharmaceuticals has reported Free Cash Flow over the past 9 years, most recently at $108.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $108.5 million for Q4 2025, up 5.46% from a year ago — trailing twelve months through Dec 2025 was $269.9 million (up 11.0% YoY), and the annual figure for FY2025 was $269.9 million, up 11.0%.
  • Free Cash Flow for Q4 2025 was $108.5 million at Amneal Pharmaceuticals, up from $106.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for AMRX hit a ceiling of $136.4 million in Q1 2021 and a floor of -$130.6 million in Q2 2022.
  • Median Free Cash Flow over the past 5 years was $70.7 million (2021), compared with a mean of $51.4 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 175.95% in 2022 and later surged 462.39% in 2023.
  • Amneal Pharmaceuticals' Free Cash Flow stood at $45.8 million in 2021, then plummeted by 175.95% to -$34.8 million in 2022, then surged by 462.39% to $126.0 million in 2023, then dropped by 18.29% to $102.9 million in 2024, then grew by 5.46% to $108.5 million in 2025.
  • The last three reported values for Free Cash Flow were $108.5 million (Q4 2025), $106.2 million (Q3 2025), and $61.0 million (Q2 2025) per Business Quant data.